英夫利昔单抗成功治疗一例复发性苏萨克综合征。

IF 0.9 Q4 CLINICAL NEUROLOGY
Case Reports in Neurological Medicine Pub Date : 2020-06-10 eCollection Date: 2020-01-01 DOI:10.1155/2020/9317232
Suran L Fernando, Therese Boyle, Annika Smith, John D E Parratt
{"title":"英夫利昔单抗成功治疗一例复发性苏萨克综合征。","authors":"Suran L Fernando,&nbsp;Therese Boyle,&nbsp;Annika Smith,&nbsp;John D E Parratt","doi":"10.1155/2020/9317232","DOIUrl":null,"url":null,"abstract":"<p><p>Susac's syndrome is a rare and debilitating disease characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. All manifestations may not be clinically apparent at presentation resulting in delayed diagnosis. Early recognition of the syndrome may prevent disease sequelae such as permanent cognitive, visual, and hearing loss. We present such a case of Susac's syndrome that was also refractory to conventionally prescribed combination of immunosuppressive treatments including high-dose potent corticosteroids, intravenous cyclophosphamide, methotrexate, plasma exchange, rituximab, and mycophenolate. His disease was stabilized with infliximab in combination with a tapering course of low-dose prednisone. After 2 years of remission with TNF treatment, consideration is being given to ceasing therapy. He has the sequelae of bilateral sensorineural hearing loss but no visual impairment or cognitive deficits on follow-up with neuropsychometric testing. This is the first case report to our knowledge of the successful use of infliximab for a patient with Susac's syndrome that was necessary following treatment with cyclophosphamide and then rituximab.</p>","PeriodicalId":9615,"journal":{"name":"Case Reports in Neurological Medicine","volume":"2020 ","pages":"9317232"},"PeriodicalIF":0.9000,"publicationDate":"2020-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9317232","citationCount":"8","resultStr":"{\"title\":\"The Successful Use of Infliximab in a Relapsing Case of Susac's Syndrome.\",\"authors\":\"Suran L Fernando,&nbsp;Therese Boyle,&nbsp;Annika Smith,&nbsp;John D E Parratt\",\"doi\":\"10.1155/2020/9317232\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Susac's syndrome is a rare and debilitating disease characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. All manifestations may not be clinically apparent at presentation resulting in delayed diagnosis. Early recognition of the syndrome may prevent disease sequelae such as permanent cognitive, visual, and hearing loss. We present such a case of Susac's syndrome that was also refractory to conventionally prescribed combination of immunosuppressive treatments including high-dose potent corticosteroids, intravenous cyclophosphamide, methotrexate, plasma exchange, rituximab, and mycophenolate. His disease was stabilized with infliximab in combination with a tapering course of low-dose prednisone. After 2 years of remission with TNF treatment, consideration is being given to ceasing therapy. He has the sequelae of bilateral sensorineural hearing loss but no visual impairment or cognitive deficits on follow-up with neuropsychometric testing. This is the first case report to our knowledge of the successful use of infliximab for a patient with Susac's syndrome that was necessary following treatment with cyclophosphamide and then rituximab.</p>\",\"PeriodicalId\":9615,\"journal\":{\"name\":\"Case Reports in Neurological Medicine\",\"volume\":\"2020 \",\"pages\":\"9317232\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2020-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2020/9317232\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Neurological Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2020/9317232\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Neurological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/9317232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 8

摘要

苏萨克综合征是一种罕见的衰弱性疾病,以脑病、视网膜分支动脉闭塞和感音神经性听力损失为特征。所有表现在临床表现时可能不明显,导致诊断延迟。早期识别该综合征可以预防疾病后遗症,如永久性的认知、视觉和听力损失。我们报告了这样一个Susac综合征的病例,该病例对常规的免疫抑制治疗组合也有难治性,包括大剂量强效皮质类固醇、静脉注射环磷酰胺、甲氨蝶呤、血浆置换、利妥昔单抗和霉酚酸盐。他的疾病在英夫利昔单抗联合小剂量强的松逐渐减少的过程中稳定下来。TNF治疗缓解2年后,考虑停止治疗。他有双侧感音神经性听力损失的后遗症,但在随访的神经心理测试中没有视觉障碍或认知缺陷。这是据我们所知的首例成功使用英夫利昔单抗治疗Susac综合征患者的病例报告,该患者在使用环磷酰胺和利妥昔单抗治疗后是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Successful Use of Infliximab in a Relapsing Case of Susac's Syndrome.

The Successful Use of Infliximab in a Relapsing Case of Susac's Syndrome.

The Successful Use of Infliximab in a Relapsing Case of Susac's Syndrome.

The Successful Use of Infliximab in a Relapsing Case of Susac's Syndrome.

Susac's syndrome is a rare and debilitating disease characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. All manifestations may not be clinically apparent at presentation resulting in delayed diagnosis. Early recognition of the syndrome may prevent disease sequelae such as permanent cognitive, visual, and hearing loss. We present such a case of Susac's syndrome that was also refractory to conventionally prescribed combination of immunosuppressive treatments including high-dose potent corticosteroids, intravenous cyclophosphamide, methotrexate, plasma exchange, rituximab, and mycophenolate. His disease was stabilized with infliximab in combination with a tapering course of low-dose prednisone. After 2 years of remission with TNF treatment, consideration is being given to ceasing therapy. He has the sequelae of bilateral sensorineural hearing loss but no visual impairment or cognitive deficits on follow-up with neuropsychometric testing. This is the first case report to our knowledge of the successful use of infliximab for a patient with Susac's syndrome that was necessary following treatment with cyclophosphamide and then rituximab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
26
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信